Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Plasminogen and the Plasminogen Receptor, Plg-RKT, Regulate Macrophage Phenotypic, and Functional Changes.

Vago JP, Sugimoto MA, Lima KM, Negreiros-Lima GL, Baik N, Teixeira MM, Perretti M, Parmer RJ, Miles LA, Sousa LP.

Front Immunol. 2019 Jun 28;10:1458. doi: 10.3389/fimmu.2019.01458. eCollection 2019.

2.

Differential expression of Plg-RKT and its effects on migration of proinflammatory monocyte and macrophage subsets.

Thaler B, Baik N, Hohensinner PJ, Baumgartner J, Panzenböck A, Stojkovic S, Demyanets S, Huk I, Rega-Kaun G, Kaun C, Prager M, Fischer MB, Huber K, Speidl WS, Parmer RJ, Miles LA, Wojta J.

Blood. 2019 Aug 8;134(6):561-567. doi: 10.1182/blood.2018850420. Epub 2019 Jun 20.

3.

The plasminogen receptor, Plg-RKT, is essential for mammary lobuloalveolar development and lactation.

Miles LA, Baik N, Bai H, Makarenkova HP, Kiosses WB, Krajewski S, Castellino FJ, Valenzuela A, Varki NM, Mueller BM, Parmer RJ.

J Thromb Haemost. 2018 May;16(5):919-932. doi: 10.1111/jth.13988. Epub 2018 Apr 1.

4.

tPA and anger management for macrophages.

Miles LA, Parmer RJ.

Blood. 2017 Sep 14;130(11):1280-1281. doi: 10.1182/blood-2017-07-795906. No abstract available.

5.

Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin.

Briens A, Bardou I, Lebas H, Miles LA, Parmer RJ, Vivien D, Docagne F.

Cell Discov. 2017 Feb 21;3:17001. doi: 10.1038/celldisc.2017.1. eCollection 2017.

6.

Deficiency of plasminogen receptor, Plg-RKT , causes defects in plasminogen binding and inflammatory macrophage recruitment in vivo.

Miles LA, Baik N, Lighvani S, Khaldoyanidi S, Varki NM, Bai H, Mueller BM, Parmer RJ.

J Thromb Haemost. 2017 Jan;15(1):155-162. doi: 10.1111/jth.13532. Epub 2016 Nov 28.

7.

Angry macrophages patrol for fibrin.

Miles LA, Parmer RJ.

Blood. 2016 Mar 3;127(9):1079-80. doi: 10.1182/blood-2016-01-687673.

8.

Setting the table for macrophages.

Miles LA, Parmer RJ.

Blood. 2014 Jul 31;124(5):665-6. doi: 10.1182/blood-2014-06-579631.

9.

New insights into the role of Plg-RKT in macrophage recruitment.

Miles LA, Lighvani S, Baik N, Parmer CM, Khaldoyanidi S, Mueller BM, Parmer RJ.

Int Rev Cell Mol Biol. 2014;309:259-302. doi: 10.1016/B978-0-12-800255-1.00005-3. Review.

10.

Peptidergic regulation of plasminogen activator inhibitor-1 gene expression in vivo.

Gingles NA, Bai H, Miles LA, Parmer RJ.

J Thromb Haemost. 2013 Sep;11(9):1707-15. doi: 10.1111/jth.12333.

11.

Plasminogen receptors: the first quarter century.

Miles LA, Parmer RJ.

Semin Thromb Hemost. 2013 Jun;39(4):329-37. doi: 10.1055/s-0033-1334483. Epub 2013 Mar 26. Review.

12.

Plasminogen receptors.

Miles LA, Plow EF, Waisman DM, Parmer RJ.

J Biomed Biotechnol. 2012;2012:130735. doi: 10.1155/2012/130735. Epub 2012 Nov 20. No abstract available.

13.

The plasminogen receptor, Plg-R(KT), and macrophage function.

Miles LA, Lighvani S, Baik N, Andronicos NM, Chen EI, Parmer CM, Khaldoyanidi S, Diggs JE, Kiosses WB, Kamps MP, Yates JR 3rd, Parmer RJ.

J Biomed Biotechnol. 2012;2012:250464. doi: 10.1155/2012/250464. Epub 2012 Oct 14. Review.

14.

The plasminogen activation system and the regulation of catecholaminergic function.

Bai H, Nangia S, Parmer RJ.

J Biomed Biotechnol. 2012;2012:721657. doi: 10.1155/2012/721657. Epub 2012 Oct 14. Review.

15.

Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.

Félez J, Jardí M, Fàbregas P, Parmer RJ, Miles LA.

Blood. 2012 Jul 19;120(3):678-81. doi: 10.1182/blood-2012-02-410480. Epub 2012 May 30.

16.

Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT.

Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA.

Blood. 2011 Nov 17;118(20):5622-30. doi: 10.1182/blood-2011-03-344242. Epub 2011 Sep 22.

17.

The novel plasminogen receptor, plasminogen receptor(KT) (Plg-R(KT)), regulates catecholamine release.

Bai H, Baik N, Kiosses WB, Krajewski S, Miles LA, Parmer RJ.

J Biol Chem. 2011 Sep 23;286(38):33125-33. doi: 10.1074/jbc.M111.218693. Epub 2011 Jul 27.

18.

Monoclonal antibodies detect receptor-induced binding sites in Glu-plasminogen.

Han J, Baik N, Kim KH, Yang JM, Han GW, Gong Y, Jardí M, Castellino FJ, Felez J, Parmer RJ, Miles LA.

Blood. 2011 Aug 11;118(6):1653-62. doi: 10.1182/blood-2010-11-316943. Epub 2011 Jun 16.

19.

The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles.

Jiang Q, Gingles NA, Olivier MA, Miles LA, Parmer RJ.

Blood. 2011 Jun 30;117(26):7155-63. doi: 10.1182/blood-2010-05-287672. Epub 2011 May 19.

20.

S100A10: a complex inflammatory role.

Miles LA, Parmer RJ.

Blood. 2010 Aug 19;116(7):1022-4. doi: 10.1182/blood-2010-05-284083. No abstract available.

PMID:
20724548
21.

PAI-1: cardiac friend or foe?

Miles LA, Parmer RJ.

Blood. 2010 Mar 11;115(10):1862-3. doi: 10.1182/blood-2010-01-261420. No abstract available.

PMID:
20223930
22.

Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation.

Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR 3rd, Parmer RJ, Miles LA.

Blood. 2010 Feb 18;115(7):1319-30. doi: 10.1182/blood-2008-11-188938. Epub 2009 Nov 6.

23.

Plasminogen enhances neuritogenesis on laminin-1.

Gutiérrez-Fernández A, Gingles NA, Bai H, Castellino FJ, Parmer RJ, Miles LA.

J Neurosci. 2009 Oct 7;29(40):12393-400. doi: 10.1523/JNEUROSCI.3553-09.2009.

24.

Plasminogen gene expression is regulated by nerve growth factor.

Gutiérrez-Fernández A, Parmer RJ, Miles LA.

J Thromb Haemost. 2007 Aug;5(8):1715-25.

25.

Cell-surface actin binds plasminogen and modulates neurotransmitter release from catecholaminergic cells.

Miles LA, Andronicos NM, Baik N, Parmer RJ.

J Neurosci. 2006 Dec 13;26(50):13017-24.

26.

Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response.

Etzel JP, Rana BK, Wen G, Parmer RJ, Schork NJ, O'Connor DT, Insel PA.

Hypertension. 2005 Jun;45(6):1207-13.

PMID:
15920038
27.

Plasminogen receptors: the sine qua non of cell surface plasminogen activation.

Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ.

Front Biosci. 2005 May 1;10:1754-62. Review.

PMID:
15769664
28.
29.

Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.

Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'connor DT.

Clin Pharmacol Ther. 2004 Aug;76(2):139-53.

PMID:
15289791
30.

Targeting of tissue plasminogen activator to the regulated pathway of secretion.

Parmer RJ, Miles LA.

Trends Cardiovasc Med. 1998 Oct;8(7):306-12.

PMID:
14987555
31.

Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.

Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O'Connor DT, Hook VY.

Biochemistry. 2003 Jun 17;42(23):6938-46.

PMID:
12795588
32.

Physical mapping of autonomic/sympathetic candidate genetic loci for hypertension in the human genome: a somatic cell radiation hybrid library approach.

Chitbangonsyn SW, Mahboubi P, Walker D, Rana BK, Diggle KL, Timberlake DS, Parmer RJ, O'Connor DT.

J Hum Hypertens. 2003 May;17(5):319-24.

PMID:
12756404
33.
34.

The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension.

O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ.

Ann N Y Acad Sci. 2002 Oct;971:533-5. No abstract available.

PMID:
12438176
35.

Catecholaminergic pathways, chromaffin cells, and human disease.

Parmer RJ, Zinder O.

Ann N Y Acad Sci. 2002 Oct;971:497-505. Review.

PMID:
12438170
36.

Chromaffin cell plasminogen receptors.

Miles LA, Hawley SB, Parmer RJ.

Ann N Y Acad Sci. 2002 Oct;971:454-9. Review. No abstract available.

PMID:
12438164
37.

The local chromaffin cell plasminogen/plasmin system and the regulation of catecholamine secretion.

Jiang Q, Yasothornsrikul S, Taupenot L, Miles LA, Parmer RJ.

Ann N Y Acad Sci. 2002 Oct;971:445-9. Review.

PMID:
12438162
38.

Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy.

Taupenot L, Harper KL, Mahapatra NR, Parmer RJ, O'Connor DT.

Ann N Y Acad Sci. 2002 Oct;971:262-5. No abstract available.

PMID:
12438129
39.

Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A.

Taupenot L, Harper KL, Mahapatra NR, Parmer RJ, Mahata SK, O'Connor DT.

J Cell Sci. 2002 Dec 15;115(Pt 24):4827-41.

40.

Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression.

Bannach FG, Gutierrez A, Fowler BJ, Bugge TH, Degen JL, Parmer RJ, Miles LA.

J Biol Chem. 2002 Oct 11;277(41):38579-88. Epub 2002 Jul 30.

41.

Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ.

J Hypertens. 2002 Jul;20(7):1335-45.

PMID:
12131530
42.

Plasminogen has a broad extrahepatic distribution.

Zhang L, Seiffert D, Fowler BJ, Jenkins GR, Thinnes TC, Loskutoff DJ, Parmer RJ, Miles LA.

Thromb Haemost. 2002 Mar;87(3):493-501.

PMID:
11916082
43.

Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release.

Jiang Q, Taupenot L, Mahata SK, Mahata M, O'Connor DT, Miles LA, Parmer RJ.

J Biol Chem. 2001 Jul 6;276(27):25022-9. Epub 2001 May 7.

44.

Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences.

O'Connor DT, Tyrell EA, Kailasam MT, Miller LM, Martinez JA, Henry RR, Parmer RJ, Gabbai FB.

Hypertension. 2001 Mar;37(3):898-906.

PMID:
11244015
45.

Molecular genetics of essential hypertension: recent results and emerging strategies.

Timberlake DS, O'Connor DT, Parmer RJ.

Curr Opin Nephrol Hypertens. 2001 Jan;10(1):71-9. Review.

PMID:
11195056
46.

Chromogranin A in human disease.

O'Connor DT, Mahata SK, Taupenot L, Mahata M, Livsey Taylor CV, Kailasam MT, Ziegler MG, Parmer RJ.

Adv Exp Med Biol. 2000;482:377-88. Review. No abstract available.

PMID:
11192598
47.

The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.

Mahata SK, Mahata M, Livsey Taylor CV, Taupenot L, Parmer RJ, O'Connor DT.

Adv Exp Med Biol. 2000;482:263-77. No abstract available.

PMID:
11192587
48.

Tissue plasminogen activator and chromaffin cell function.

Parmer RJ, Mahata SK, Jiang Q, Taupenot L, Gong Y, Mahata M, O'Connor DT, Miles LA.

Adv Exp Med Biol. 2000;482:179-92. Review. No abstract available.

PMID:
11192579
49.

Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity.

Lacy F, Kailasam MT, O'Connor DT, Schmid-Schönbein GW, Parmer RJ.

Hypertension. 2000 Nov;36(5):878-84.

PMID:
11082160
50.

Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.

Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT.

J Hypertens. 2000 Nov;18(11):1611-20.

PMID:
11081774

Supplemental Content

Loading ...
Support Center